Cellbyte, founded by Felix Steinbrenner and Daniel Moreira, has built an AI-native platform tailored for commercial teams planning new drug launches. The software ingests millions of clinical, pricing, HTA, regulatory and internal data points, then surfaces real-time insights to prepare launch documents, sequence markets and craft go-to-market strategies. By automating these processes, the platform shortens launch timelines and reduces operational complexity for pharma customers. The company expanded coverage to key global markets soon after launch and has already secured enterprise contracts with industry leaders such as Bayer. Cellbyte achieved six-figure annual recurring revenue within weeks and continues to post rapid ARR growth. With fresh capital, the team plans to triple headcount and bolster engineering capabilities as it strives to become the operating system for commercial pharmaceutical teams worldwide.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Nov 2025